These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3959968)

  • 41. Maintenance agonist treatments for opiate-dependent pregnant women.
    Minozzi S; Amato L; Bellisario C; Ferri M; Davoli M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD006318. PubMed ID: 24366859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.
    Stine SM; Kosten TR
    Am J Drug Alcohol Abuse; 1994 Nov; 20(4):445-58. PubMed ID: 7832179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of buprenorphine in heroin addicts.
    Blom Y; Bondesson U; Gunne LM
    Drug Alcohol Depend; 1987 Sep; 20(1):1-7. PubMed ID: 3678038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naltrexone shortened opioid detoxification with buprenorphine.
    Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
    Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study.
    Lintzeris N; Bammer G; Rushworth L; Jolley DJ; Whelan G
    Drug Alcohol Depend; 2003 Jun; 70(3):287-94. PubMed ID: 12757966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Buprenorphine replacement therapy: a confirmed benefit.
    Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of intravenous buprenorphine for the treatment of opioid withdrawal in medically ill hospitalized patients.
    Welsh CJ; Suman M; Cohen A; Broyles L; Bennett M; Weintraub E
    Am J Addict; 2002; 11(2):135-40. PubMed ID: 12028743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.
    Sobel BF; Sigmon SC; Walsh SL; Johnson RE; Liebson IA; Nuwayser ES; Kerrigan JH; Bigelow GE
    Drug Alcohol Depend; 2004 Jan; 73(1):11-22. PubMed ID: 14687955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Reimbursement of opiate substitution drugs to militaries in 2007].
    d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V
    Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined buprenorphine and chlonidine for short-term opiate detoxification: patient perspectives.
    Wallen MC; Lorman WJ; Gosciniak JL
    J Addict Dis; 2006; 25(1):23-31. PubMed ID: 16597570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of a high-dose fast tapering buprenorphine detoxification program on symptom relief and treatment retention.
    Palmstierna T
    J Psychoactive Drugs; 2004 Jun; 36(2):273-7. PubMed ID: 15369209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
    Jasinski DR; Pevnick JS; Griffith JD
    Arch Gen Psychiatry; 1978 Apr; 35(4):501-16. PubMed ID: 215096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.
    Comer SD; Collins ED; Fischman MW
    Psychopharmacology (Berl); 2001 Feb; 154(1):28-37. PubMed ID: 11292003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Buprenorphine vs. methadone as maintenance treatment for opioid dependence].
    Fischer G; Gombas W; Eder H; Jagsch R; Stühlinger G; Aschauer HN; Kasper S
    Nervenarzt; 1999 Sep; 70(9):795-802. PubMed ID: 10522247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of buprenorphine and methadone effects on opiate self-administration in primates.
    Mello NK; Bree MP; Mendelson JH
    J Pharmacol Exp Ther; 1983 May; 225(2):378-86. PubMed ID: 6188822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.